neuroClues, a MedTech company focused on neurological diagnostics, has raised €10 million in a Series A round, alongside additional non-dilutive funding, bringing total capital raised to €25 million.
The round was led by Teampact Ventures, White Fund, and EIC Fund, with participation from existing investors including InvestBW, Leansquare, and Wallonie Entreprendre. The funding will support the scaling of its AI-powered diagnostic platform across Europe.
What The Company Does
Founded in 2020 by Antoine Pouppez, Pierre Daye, and Pierre Pouget, neuroClues develops a compact, non-invasive medical device that analyzes eye movements to detect neurological disorders.
The company’s CE-marked system uses high-speed infrared sensors to capture eye movement data during simple visual tasks. This data is processed באמצעות artificial intelligence to generate objective neurological biomarkers, supporting clinicians in diagnosing and monitoring conditions with greater precision.
By translating eye movement patterns into measurable indicators, the platform aims to provide an alternative to traditional diagnostic methods, which often rely on subjective clinical observation or costly imaging techniques.
Advertisement
Market Context / Industry Background
Neurodegenerative diseases represent a growing healthcare challenge, affecting a significant portion of the global population and frequently being diagnosed at later stages, which complicates treatment and management. Early detection remains difficult, as existing diagnostic pathways can lack sensitivity in identifying subtle initial symptoms and may depend heavily on subjective clinical evaluation.
Healthcare systems across Europe are increasingly prioritizing scalable and accessible diagnostic tools that can support earlier intervention and reduce long-term treatment costs, especially in aging populations. Technologies that combine non-invasive data collection with AI-driven analysis are gaining traction as they offer the potential to standardize diagnosis and improve clinical outcomes.
neuroClues operates within this evolving landscape, positioning its solution as a tool that can enhance both clinical practice and research by providing consistent, data-driven insights that may support more reliable assessments over time. These developments reflect a broader shift toward integrating digital tools into routine healthcare workflows across multiple clinical settings, reinforcing the importance of innovation in addressing complex diagnostic challenges and improving overall system efficiency globally.
Founder / Investor Commentary
Chief Executive Officer Antoine Pouppez noted that the Series A round reflects both technological validation and operational progress. He highlighted key milestones, including rapid CE certification, early commercial deployments, and the development of a large-scale clinical database.
He emphasized that the platform provides clinicians with an objective method to assess neurological anomalies, adding that as the dataset expands, the system will improve its ability to identify specific pathologies at earlier stages and with greater accuracy.
Growth Plans / Use Of Funds
The newly raised capital will be used to accelerate commercial deployment across European markets, expand clinical partnerships, and further develop the company’s AI models. neuroClues has already deployed more than 30 devices across countries including France, Belgium, Germany, and the United Kingdom, spanning hospitals, clinics, and research institutions.
The company is also contributing to a large-scale clinical study involving 25,000 patients, aimed at building one of the most comprehensive databases of eye-movement biomarkers. Additional initiatives include collaboration with the Paris Brain Institute and participation in international programs such as Bpifrance’s National Prevention Accelerator.
To support its expansion, neuroClues has strengthened its leadership team with the appointment of Bart Stulens and is continuing to grow its workforce across Europe. The company has also opened a €1.5 million investment opportunity via LITA to broaden investor participation.
About neuroClues
neuroClues is a French-Belgian MedTech company developing AI-powered diagnostic tools for neurological disorders. Founded in 2020, the company focuses on non-invasive eye-tracking technology to generate objective biomarkers for early detection and monitoring. Its mission is to improve neurological care through accessible, data-driven diagnostics.
